Power of proteomics and progress in precision medicine – 13th central and eastern European proteomic conference (CEEPC), Ustroń, Poland

ABSTRACT

Introduction

Central and Eastern European Proteomic Conference (CEEPC) provides a platform for researchers to discuss multi-disciplinary integrated approaches to address a range of challenges from present day viral pandemic to on-going progress in Precision Medicine. CEEPC brings together various multi-omics entwined with novel enabling technologies, thus facilitating conceptual advances from cell to society for the benefit of mankind.

Areas covered

Proteomic methodologies, databases and software has revolutionized our ability to assess protein interactions and cellular changes, allowing the establishment of biological connections and identification of important cellular regulatory proteins and pathways previously unknown or not fully understood. Additionally, Mass spectrometry (MS) remains a major driving force in the field of ‘multi-omics’ and a powerful technology for the structural characterization of biomolecules and for analysis of proteins and small molecules such as lipids, sugars and metabolites. Combination of measurements from proteomics, genomics, epigenomics, transcriptomics and metabolomics, present a powerful decision-making format allowing deeper interpretation of a disease scenario in Precision medicine.

Expert commentary

Precision Medicine offers novel and promising ways to identify and treat a wide range of diseases. The future success of these therapies will be underpinned by novel proteo-genomic approaches linked to sophisticated databases to evaluate and predict drug-patient interactions.

KEYWORDS:

• Biomarkers
• multi-proteomics
• cancer
• clinical proteomics
• exosomes
• mass Spectrometry Imaging
• viral proteomics
• precision medicine
• systems Biology
• socio-humanitarian

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.